@article{6dd69d57894644d496e28b3bbac86c37,
title = "An assessment by the statin intolerance panel: 2014 update",
abstract = "This article from the National Lipid Association Statin Intolerance Panel provides a framework for understanding statin intolerance and makes general recommendations for health professionals. For specific guidance on adverse events related to muscle, liver, cognition, and glucose metabolism, one should refer to the other reports of the Statin Safety Task Force for those topics. Although statin adverse effects rarely lead to permanent sequelae, symptomatic intolerance frequently hinders cardiovascular risk reduction by statins. We emphasize here the advisory role of the clinician helping each patient to make personal decisions on statin tolerability. We identify a pressing need for further research on statin intolerance and make suggestions for research design.",
keywords = "Drug intolerance, Patient-centered medicine, Statin adverse effects, Statin safety, Statins",
author = "Guyton, {John R.} and Bays, {Harold E.} and Grundy, {Scott M} and Jacobson, {Terry A.}",
note = "Funding Information: The following authors disclose that they have modest relationships with industry that might pose a potential conflict of interest(s). Dr. Guyton has received research grants from Merck, Abbott, Genzyme, Sanofi, Regeneron, GSK, Amarin, and Amgen and consulting fees from Merck, Regeneron, and ARMO Biosciences. Dr. Harold Bays has served as a consultant and/or speaker to Amarin, Amgen, Astra Zeneca, Bristol Meyers Squibb, Catabasis, Daiichi Sankyo, Eisai, Isis, Merck, Novartis, VIVUS, WPU, and his research site has received research grants from Alere, Amarin, Amgen, Ardea, Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, California Raisin Board, Catabasis, Eisai, Elcelyx, Eli Lilly, Esperion, Essentialis, Forest, Gilead, Given, GlaxoSmithKline, High Point Pharmaceuticals LLC, Hoffman LaRoche, Home Access, Janssen, Merck, Metabolex, Micropharma Limited, Necktar, Novartis, Novo Nordisk, Omthera, Orexigen, Pfizer, Pronova, Regeneron, Stratum Nutrition, Takeda, TIMI, Transtech Pharma, Trygg, VIVUS, WPU, and Xoma. Dr. Scott Grundy discloses that he has received an honorarium as a consultant to Sanofi. Dr. Jacobson is a consultant for Amarin, Amgen, Astra Zeneca, Merck, Sanofi, and Regeneron.",
year = "2014",
doi = "10.1016/j.jacl.2014.03.002",
language = "English (US)",
volume = "8",
pages = "S72--S81",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "3 SUPPL",
}